roon schreef op 5 december 2023 12:10:
[...]
zo een berichtje moeten we hebben.......in december.
Vanda Pharmaceuticals Shares Rise Premarket on FDA Review of Tradipitant
< 1 minuten geleden (vandaag 12:08:06)
Dow Jones Newswires
By Colin Kellaher
Shares of Vanda Pharmaceuticals rose sharply in premarket trading Tuesday after the biopharmaceutical company said the U.S. Food and Drug Administration accepted its application seeking approval of tradipitant for the treatment of symptoms of the digestive condition gastroparesis.
After the closing bell Monday, Vanda said the FDA set a target action date of Sept. 18, 2024, for the application.
Vanda said an FDA green light would make tradipitant the first novel drug approved by the agency in more than four decades for gastroparesis, which prevents the stomach from emptying properly.
Vanda shares, which closed Monday at $3.85, were recently up nearly 19% to $4.57 in light premarket trading.